Income Statement (TTM)
Akums Drugs and Pharmaceuticals Limited Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2021 03-31 |
2022 03-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27,262 | 36,752 | 36,572 | 37,158 | 39,875 | 41,513 | 41,817 | 42,309 | 40,827 | 40,103 | 41,211 | 41,260 |
| Change (%) | 34.81 | -0.49 | 1.60 | 7.31 | 4.11 | 0.73 | 1.18 | -3.50 | -1.77 | 2.76 | 0.12 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 17,343 | 24,145 | 23,493 | 23,363 | 24,633 | 25,490 | 26,204 | 26,228 | 25,171 | 24,338 | 24,993 | 24,852 |
| Change (%) | 39.22 | -2.70 | -0.55 | 5.43 | 3.48 | 2.80 | 0.09 | -4.03 | -3.31 | 2.69 | -0.56 | |
| % of Revenue | 63.62 | 65.70 | 64.24 | 62.87 | 61.78 | 61.40 | 62.66 | 61.99 | 61.65 | 60.69 | 60.65 | 60.23 |
| Gross Operating Profit | 9,919 | 12,607 | 13,079 | 13,795 | 15,242 | 16,023 | 15,613 | 16,081 | 15,656 | 15,765 | 16,218 | 16,408 |
| Change (%) | 27.10 | 3.74 | 5.48 | 10.49 | 5.13 | -2.56 | 3.00 | -2.64 | 0.69 | 2.87 | 1.17 | |
| % of Revenue | 36.38 | 34.30 | 35.76 | 37.13 | 38.22 | 38.60 | 37.34 | 38.01 | 38.35 | 39.31 | 39.35 | 39.77 |
| SG&A | 4,541 | 5,399 | 6,291 | 6,258 | 6,555 | 6,376 | 6,918 | 7,115 | 7,277 | 7,408 | 7,573 | 7,572 |
| Change (%) | 18.89 | 16.53 | -0.52 | 4.74 | -2.72 | 8.50 | 2.84 | 2.28 | 1.80 | 2.22 | -0.01 | |
| % of Revenue | 16.66 | 14.69 | 17.20 | 16.84 | 16.44 | 15.36 | 16.54 | 16.82 | 17.82 | 18.47 | 18.38 | 18.35 |
| R&D | ||||||||||||
| Change (%) | ||||||||||||
| % of Revenue | ||||||||||||
| OpEx | 25,006 | 33,594 | 34,677 | 34,834 | 36,305 | 37,829 | 38,171 | 38,519 | 37,674 | 36,989 | 38,027 | 38,056 |
| Change (%) | 34.34 | 3.22 | 0.45 | 4.22 | 4.20 | 0.90 | 0.91 | -2.20 | -1.82 | 2.81 | 0.08 | |
| % of Revenue | 91.72 | 91.41 | 94.82 | 93.75 | 91.05 | 91.13 | 91.28 | 91.04 | 92.28 | 92.23 | 92.27 | 92.23 |
| Operating Income | 2,256 | 3,158 | 1,895 | 2,324 | 3,570 | 3,684 | 3,646 | 3,790 | 3,154 | 3,114 | 3,185 | 3,204 |
| Change (%) | 39.99 | -40.00 | 22.66 | 53.59 | 3.20 | -1.04 | 3.95 | -16.78 | -1.25 | 2.26 | 0.62 | |
| % of Revenue | 8.28 | 8.59 | 5.18 | 6.25 | 8.95 | 8.87 | 8.72 | 8.96 | 7.72 | 7.77 | 7.73 | 7.77 |
| Interest Expense | -64 | -163 | -460 | -492 | -538 | -523 | -503 | -511 | -494 | -421 | -304 | -405 |
| Change (%) | 155.76 | 181.39 | 6.94 | 9.52 | -2.94 | -3.85 | 1.74 | -3.42 | -14.79 | -27.73 | 33.26 | |
| % of Revenue | -0.23 | -0.44 | -1.26 | -1.32 | -1.35 | -1.26 | -1.20 | -1.21 | -1.21 | -1.05 | -0.74 | -0.98 |
| Net Income | 1,227 | -2,525 | 949 | -1,277 | -1,302 | 504 | -40 | 2,444 | 2,778 | 1,492 | 3,382 | 3,415 |
| Change (%) | -305.81 | -137.56 | -234.60 | 1.95 | -138.73 | -108.00 | -6,156.11 | 13.67 | -46.27 | 126.60 | 0.98 | |
| % of Revenue | 4.50 | -6.87 | 2.59 | -3.44 | -3.26 | 1.21 | -0.10 | 5.78 | 6.80 | 3.72 | 8.21 | 8.28 |
Source: Capital IQ
